BRPI0412347A - 2-aminofenil-4-fenilpiridinas como inibidores de quinase - Google Patents
2-aminofenil-4-fenilpiridinas como inibidores de quinaseInfo
- Publication number
- BRPI0412347A BRPI0412347A BRPI0412347-6A BRPI0412347A BRPI0412347A BR PI0412347 A BRPI0412347 A BR PI0412347A BR PI0412347 A BRPI0412347 A BR PI0412347A BR PI0412347 A BRPI0412347 A BR PI0412347A
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- aminophenyl
- phenylpyridines
- compounds
- phenylpyrimidines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
"2-AMINOFENIL-4-FENILPIRIMIDINAS COMO INIBIDORES DE QUINASE". A presente invenção refere-se a compostos de Fórmula (I) ou um sal farmaceuticamente aceitável do mesmo, em que as variáveis são como definidas no relatório. Os compostos agem como inibidores de quinase.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0317841.5A GB0317841D0 (en) | 2003-07-30 | 2003-07-30 | Compound |
GB0318345A GB0318345D0 (en) | 2003-08-05 | 2003-08-05 | Compound |
PCT/GB2004/003284 WO2005012262A1 (en) | 2003-07-30 | 2004-07-30 | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0412347A true BRPI0412347A (pt) | 2006-09-05 |
Family
ID=34117649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412347-6A BRPI0412347A (pt) | 2003-07-30 | 2004-07-30 | 2-aminofenil-4-fenilpiridinas como inibidores de quinase |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070021419A1 (pt) |
EP (1) | EP1648875A1 (pt) |
JP (1) | JP2007500179A (pt) |
AU (1) | AU2004261484A1 (pt) |
BR (1) | BRPI0412347A (pt) |
CA (1) | CA2533474A1 (pt) |
IL (1) | IL173381A0 (pt) |
WO (1) | WO2005012262A1 (pt) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
DK1534286T3 (da) | 2002-07-29 | 2010-04-26 | Rigel Pharmaceuticals Inc | Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser |
GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
PT1656372E (pt) | 2003-07-30 | 2013-06-27 | Rigel Pharmaceuticals Inc | Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina |
SI1689715T1 (sl) * | 2003-12-03 | 2011-07-29 | Ym Biosciences Australia Pty | Inhibitorji tubulina |
GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
AU2005286592A1 (en) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
WO2006044687A2 (en) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス,インコーポレイティド | 神経発生のgaba受容体媒介調節 |
JP2009514876A (ja) * | 2005-11-03 | 2009-04-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼのための化合物および組成物 |
EP1979329A2 (en) * | 2006-01-30 | 2008-10-15 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use |
WO2007095603A2 (en) * | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
WO2008065155A1 (en) * | 2006-11-30 | 2008-06-05 | Ingenium Pharmaceuticals Gmbh | Cdk inhibitors for treating pain |
AU2013201306B2 (en) * | 2007-03-12 | 2015-11-12 | Glaxosmithkline Llc | Phenyl Amino Pyrimidine Compounds and Uses Thereof |
PL2152701T3 (pl) * | 2007-03-12 | 2016-10-31 | Związki fenyloaminopirymidyny i ich zastosowania | |
AU2016200866B2 (en) * | 2007-03-12 | 2017-06-22 | Glaxosmithkline Llc | Phenyl amino pyrimidine compounds and uses thereof |
JP5566880B2 (ja) | 2007-04-24 | 2014-08-06 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体 |
JP5693951B2 (ja) * | 2007-04-24 | 2015-04-01 | アストラゼネカ エービー | プロテインキナーゼの阻害剤 |
US8507511B2 (en) * | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
US8530480B2 (en) | 2007-09-04 | 2013-09-10 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
ATE510827T1 (de) | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
WO2009103032A1 (en) | 2008-02-15 | 2009-08-20 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
WO2009107391A1 (ja) * | 2008-02-27 | 2009-09-03 | 武田薬品工業株式会社 | 6員芳香環含有化合物 |
GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN102834380B (zh) | 2010-03-10 | 2015-04-01 | 阿斯利康公司 | 蛋白激酶的抑制剂 |
GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
US20130303507A1 (en) * | 2011-01-28 | 2013-11-14 | Novartis Ag | Substituted hetero-biaryl compounds and their uses |
JP6147727B2 (ja) | 2011-04-01 | 2017-06-14 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼbtk阻害剤としての置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体 |
JP2014510794A (ja) * | 2011-04-12 | 2014-05-01 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド | IKK関連キナーゼεおよびTANK結合キナーゼ1の阻害剤の組成物および治療的使用 |
DE102011112978A1 (de) | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
KR101452235B1 (ko) * | 2012-02-03 | 2014-10-22 | 서울대학교산학협력단 | 신규한 피리미딘계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 rage 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2013175415A1 (en) * | 2012-05-23 | 2013-11-28 | Piramal Enterprises Limited | Substituted pyrimidine compounds and uses thereof |
US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
LT2887943T (lt) * | 2012-08-23 | 2018-05-25 | Virostatics Srl | Nauji 4,6-di-pakeistieji aminopirimidino dariniai |
JP6313772B2 (ja) * | 2012-10-04 | 2018-04-18 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼbtk阻害剤である置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体 |
JP6401169B2 (ja) | 2012-10-04 | 2018-10-03 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼbtk阻害剤としての置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体 |
GB201303109D0 (en) | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
CA3000633C (en) | 2014-10-14 | 2023-10-03 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
GB201702947D0 (en) | 2017-02-23 | 2017-04-12 | Domainex Ltd | Novel compounds |
US10543212B2 (en) | 2017-03-27 | 2020-01-28 | Cardurion Pharmaceuticals, Llc | Substituted amines for treating cardiac diseases |
GB201809102D0 (en) * | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
MX2021003516A (es) | 2018-09-25 | 2021-05-27 | Cardurion Pharmaceuticals Llc | Compuesto de aminopirimidina. |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
PE20221010A1 (es) | 2019-08-14 | 2022-06-15 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
JP2022551668A (ja) | 2019-10-11 | 2022-12-12 | インサイト・コーポレイション | Cdk2阻害剤としての二環式アミン |
CN115703760A (zh) * | 2021-08-11 | 2023-02-17 | 山东大学 | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 |
WO2023150197A1 (en) * | 2022-02-03 | 2023-08-10 | Nexys Therapeutics, Inc. | Aryl hydrocarbon receptor agonists and uses thereof |
WO2023247552A1 (en) | 2022-06-21 | 2023-12-28 | Syngenta Crop Protection Ag | Microbiocidal bicyclic heterocyclic carboxamide derivatives |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US243440A (en) * | 1881-06-28 | Gbeen freeman | ||
US2433439A (en) * | 1947-12-30 | Pyrimidine compounds | ||
GB8412184D0 (en) * | 1984-05-12 | 1984-06-20 | Fisons Plc | Biologically active nitrogen heterocycles |
EP0164204A1 (en) | 1984-05-12 | 1985-12-11 | FISONS plc | Novel pharmaceutically useful pyrimidines |
AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US6306866B1 (en) * | 1998-03-06 | 2001-10-23 | American Cyanamid Company | Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
AU2001242629B2 (en) * | 2000-03-29 | 2005-08-11 | Cyclacel Limited | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
SE0002770D0 (sv) | 2000-07-25 | 2000-07-25 | Biomat System Ab | a method of producing a body by adiabatic forming and the body produced |
US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
ES2265450T3 (es) * | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de la proteina quinasa. |
ES2292753T4 (es) * | 2001-03-29 | 2009-02-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas. |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
TW200302728A (en) * | 2002-02-01 | 2003-08-16 | Novartis Ag | Substituted amines as IgE inhibitors |
WO2003082263A1 (en) | 2002-03-29 | 2003-10-09 | Ontogen Corporation | Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases |
DK1534286T3 (da) * | 2002-07-29 | 2010-04-26 | Rigel Pharmaceuticals Inc | Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser |
US7304071B2 (en) * | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
DE60330895D1 (de) * | 2002-11-01 | 2010-02-25 | Vertex Pharma | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen |
JP2006508107A (ja) | 2002-11-05 | 2006-03-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakおよび他のプロテインキナーゼのインヒビターとして有用な化合物 |
JP4330353B2 (ja) * | 2003-02-21 | 2009-09-16 | 株式会社静岡カフェイン工業所 | ピリミジン誘導体 |
KR20060052806A (ko) * | 2003-07-25 | 2006-05-19 | 시바 스폐셜티 케미칼스 홀딩 인코포레이티드 | 항균제로서 치환된 2,4-비스(알킬아미노)피리미딘 또는-퀴나졸린의 용도 |
-
2004
- 2004-07-30 CA CA002533474A patent/CA2533474A1/en not_active Abandoned
- 2004-07-30 AU AU2004261484A patent/AU2004261484A1/en not_active Abandoned
- 2004-07-30 JP JP2006521665A patent/JP2007500179A/ja active Pending
- 2004-07-30 BR BRPI0412347-6A patent/BRPI0412347A/pt not_active IP Right Cessation
- 2004-07-30 WO PCT/GB2004/003284 patent/WO2005012262A1/en active Application Filing
- 2004-07-30 EP EP04743610A patent/EP1648875A1/en not_active Withdrawn
-
2006
- 2006-01-25 US US11/339,058 patent/US20070021419A1/en not_active Abandoned
- 2006-01-26 IL IL173381A patent/IL173381A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2533474A1 (en) | 2005-02-10 |
AU2004261484A1 (en) | 2005-02-10 |
EP1648875A1 (en) | 2006-04-26 |
JP2007500179A (ja) | 2007-01-11 |
US20070021419A1 (en) | 2007-01-25 |
WO2005012262A1 (en) | 2005-02-10 |
IL173381A0 (en) | 2006-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
BRPI0417543A (pt) | quinolinas úteis no tratamento de doença cardiovascular | |
BRPI0518581A2 (pt) | compostos de cromanilurÉia que inibem o receptor do subtipo 1 do recepetor vanilàide (vr1) e usos destes | |
UY29963A1 (es) | Compuestos terapéuticos: piridinas y pirazinas como andamios | |
HRP20040686B1 (hr) | Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza | |
BRPI0418031A (pt) | inibidores de quinase fosfonato-substituìdos | |
BRPI0507617A (pt) | antagonistas de receptor de quimiocina | |
ATE433981T1 (de) | Heterocyclische verbindungen | |
EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
BR0317455A (pt) | Derivados de pirrol-pirazol substituìdos como inibidores de quinase | |
ES2368594T3 (es) | Derivados sustituidos de ciclohexilmetilo. | |
BR0309556A (pt) | Inibidores de metaloproteinase pirimidina-2,4,6-triona | |
BR0316375A (pt) | Diazinopirimidinas | |
BR0314379A (pt) | Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase | |
MX2007013624A (es) | Inhibidores de proteina cinasa. | |
BRPI0507903A (pt) | derivados de quinazolina e composição farmacêutica compreendendo os mesmos | |
BR0207278A (pt) | Derivados de ftalazinona-piperidina como inibidores de pde4 | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
MY148988A (en) | Terphenyl derivatives for treatment of alzheimer's disease | |
ATE477256T1 (de) | Thienylverbindungen | |
BRPI0414573A (pt) | 7-amino alquilidenil-quinolonas e naftiridonas heterocìclicas | |
DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
BRPI0519267A2 (pt) | derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo | |
BRPI0407282A (pt) | Processo para preparação de inibidores de pirrolotriazina cinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |